Dual inhibition of mTORC1/C2 and HER2 results in maximal antitumor efficacy in preclinical model of HER2+breast cancer resistant to trastuzumab therapy

被引：1
|
作者：
De, Pradip Kr [1 ]
Sun, Yuliang [1 ]
Carlson, Jennifer H. [1 ]
Lin, Xiaoqian [1 ]
Dey, Nandini [1 ]
Leyland-Jones, Brian [1 ]
机构：
[1] Avera Res Inst, Sioux Falls, SD USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-1940
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1940
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Dual MTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
    Garcia-Garcia, C.
    Ibrahim, Y. H.
    Serra, V.
    Calvo, M. T.
    Aura, C.
    Perez, J.
    Rommel, C.
    Tabernero, J.
    Baselga, J.
    Scaltriti, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S192 - S192
  • [2] Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
    Garcia-Garcia, Celina
    Ibrahim, Yasir H.
    Serra, Violeta
    Teresa Calvo, Maria
    Guzman, Marta
    Grueso, Judit
    Aura, Claudia
    Perez, Jose
    Jessen, Katti
    Liu, Yi
    Rommel, Christian
    Tabernero, Josep
    Baselga, Jose
    Scaltriti, Maurizio
    CLINICAL CANCER RESEARCH, 2012, 18 (09) : 2603 - 2612
  • [3] Dual PI3K/mTOR and HER2 Blockade Results in Antitumor Efficacy in Preclinical Models of HER2+Breast Cancer Resistant to Trastuzumab Therapy
    De, P.
    Sun, Y.
    Dey, N.
    Leyland-Jones, B.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 114 - 115
  • [4] Dual HER2 blockage with lapatinib and trastuzumab for Japanese patients with HER2+breast cancer
    Iwata, H.
    Yamamoto, N.
    Masuda, N.
    Bando, H.
    Kuroi, K.
    Ohno, S.
    Kasai, H.
    Morita, S.
    Sakurai, T.
    Toi, M.
    BREAST, 2015, 24 : S95 - S95
  • [5] A combination of dual inhibition in HER2-network by T-DM1 and GDC-0980 provides maximal antitumor efficacy in preclinical model of HER2+breast cancer
    De, P. K.
    Carlson, J. H.
    Sun, Y.
    Lin, X.
    Friedman, L.
    Dey, N.
    Leyland-Jones, B.
    CANCER RESEARCH, 2017, 77
  • [6] Dual inhibition of the PI3K-mTOR signaling in combination with HER2 inhibitor is necessary for maximal antitumor activity in HER2+breast cancer cells
    De, Pradip
    Sun, Yuliang
    Carlson, Jennifer
    Friedman, Lori
    Dey, Nandini
    Leyland-Jones, Brian
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [7] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Sumanpreet Kaur
    Rajasri Bhattacharyya
    Dibyajyoti Banerjee
    Jaya Shukla
    Indian Journal of Clinical Biochemistry, 2021, 36 : 124 - 125
  • [8] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Kaur, Sumanpreet
    Bhattacharyya, Rajasri
    Banerjee, Dibyajyoti
    Shukla, Jaya
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2021, 36 (01) : 124 - 125
  • [9] Recent Insights into the Development of Preclinical Trastuzumab-Resistant HER2+Breast Cancer Models
    Gonzalez-Alonso, Paula
    Cristobal, Ion
    Zazo, Sandra
    Martin-Aparicio, Ester
    Chamizo, Cristina
    Madoz-Gurpide, Juan
    Rovira, Ana
    Eroles, Pilar
    Lluch, Ana
    Albanell, Joan
    Rojo, Federico
    CURRENT MEDICINAL CHEMISTRY, 2018, 25 (17) : 1976 - 1998
  • [10] Dual inhibition of HER2 in breast cancer treatment
    Gnant, Michael
    Steger, Guenther G.
    LANCET, 2012, 379 (9816): : 596 - 598
12345